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OBJECTIVE: We aimed to evaluate angiotensin receptor blocker add-on therapy in patients with low cardiac
output during decompensated heart failure.
METHODS: We selected patients with decompensated heart failure, low cardiac output, dobutamine
dependence, and an ejection fraction ,0.45 who were receiving an angiotensin-converting enzyme inhibitor.
The patients were randomized to losartan or placebo and underwent invasive hemodynamic and B-type
natriuretic peptide measurements at baseline and on the seventh day after intervention. ClinicalTrials.gov:
NCT01857999.
RESULTS: We studied 10 patients in the losartan group and 11 patients in the placebo group. The patient
characteristics were as follows: age 52.7 years, ejection fraction 21.3%, dobutamine infusion 8.5 mcg/kg.min,
indexed systemic vascular resistance 1918.0 dynes.sec/cm5.m2, cardiac index 2.8 L/min.m2, and B-type natriuretic
peptide 1,403 pg/mL. After 7 days of intervention, there was a 37.4% reduction in the B-type natriuretic
peptide levels in the losartan group compared with an 11.9% increase in the placebo group (mean difference, -
49.1%; 95% confidence interval: -88.1 to -9.8%, p=0.018). No significant difference was observed in the
hemodynamic measurements.
CONCLUSION: Short-term add-on therapy with losartan reduced B-type natriuretic peptide levels in patients
hospitalized for decompensated severe heart failure and low cardiac output with inotrope dependence.
KEYWORDS: Renin-Aldosterone System; Hemodynamic; Low Cardiac Output; Vasodilation; Natriuretic Peptide.
Ochiai ME, Brancalha˜o EC, Puig RS, Vieira KR, Cardoso JN, Oliveira-Jr MT, et al. Short-term add-on therapy with angiotensin receptor blocker for
end-stage inotrope-dependent heart failure patients: B-type natriuretic peptide reduction in a randomized clinical trial. Clinics. 2014;69(5):308-
313.
Received for publication on July 1, 2013; First review completed on August 8, 2013; Accepted for publication on September 27, 2013
E-mail: marcelo.ochiai@incor.usp.br
Tel.: 55 11 2661-5417
& INTRODUCTION
The management approach for stable chronic heart failure
has been established by guidelines (1) that were developed
using data from randomized clinical trials. However, during
heart failure, decompensation-specific interventions have
not been well studied. Moreover, heart failure patients
require hospitalization, and sometimes they are in critical
condition, presenting problems such as a low cardiac
output. In this context, fewer clinical trials have been
performed.
The intravenous administration of inotropes may be
necessary for heart failure patients with low cardiac output
if intravenous vasodilator therapy is not possible (2). In end-
stage heart failure, patients frequently become dependent
on inotrope, which predicts greater mortality (3). Generally,
these patients die if they cannot receive a heart transplant,
either because of clinical conditions or because of the lack of
available donor organs. Therefore, it is important to find
alternative options so that inotropes can be withdrawn as
soon as possible.
During decompensated heart failure, activation of the
renin-angiotensin-aldosterone system persists, with increases
in plasma renin activity and serum levels of angiotensin II
and aldosterone, despite the use of angiotensin-converting
enzyme (ACE) inhibitors (4). In advanced heart failure
patients, a state of low cardiac output could be present
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during a decompensated period; consequently, the use of
ACE inhibitors might not be adequate for controlling
vasoconstriction (5).
Although many clinical trials have been performed to
examine drug therapies for stable chronic heart failure,
clinical trials are lacking for drug therapy during decom-
pensated heart failure, mainly with inotrope dependence (6).
In this context, short-term outcomes should have priority (7).
The dual blockade of the renin-angiotensin-aldosterone
system with an ACE inhibitor and an AT1 angiotensin
receptor blocker (ARB) used together has been demon-
strated to be beneficial in heart failure patients (8,9).
However, this dual inhibition has not been studied during
heart failure decompensation or even when low cardiac
output is present.
The objective of this study was to assess the effects of add-
on therapy with angiotensin receptor blocker on plasma B-
type natriuretic peptide (BNP) levels and hemodynamic
measurements in heart failure patients with low cardiac
output during hospitalization for decompensation.
& METHODS
This study was carried out in the heart failure compensa-
tion unit of a tertiary cardiology center at a university
hospital. Patients who are typically hospitalized in our
medical facility are those with severe advanced heart failure
in a decompensation period that does not respond to initial
therapy; frequently, these patients present with low cardiac
output (10). In our service, dobutamine is preferred over
milrinone. It is not uncommon for some patients to
experience dobutamine dependence and not be able to
tolerate inotropic withdrawal.
Patients
This was a randomized, double-blind, placebo-controlled
clinical trial. The inclusion criteria were as follows:
hospitalization for decompensated heart failure, defined
by worsening of symptoms until fatigue or dyspnea at rest;
low cardiac output, defined by the clinical-hemodynamic
profile (4); dobutamine dependence; ejection fraction ,0.45;
spontaneous breathing; and receiving ACE inhibitors. The
patients could have jugular ingurgitation, lower limb
edema, ascites, and rales. Dobutamine dependence was
defined by infusion for more than 15 days or an unsuccess-
ful attempt at withdrawal. The exclusion criteria were as
follows: serum creatinine .3.0 mg/dL, serum K.6.0 mEq/
L, systolic blood pressure ,70 mm Hg, aortic stenosis, and
acute coronary syndrome in the previous 2 months. The
patients were then assigned by permuted block randomiza-
tion to 4 groups, stratified by sex, to losartan or placebo. The
endpoints were changes in the BNP levels, cardiac index,
pulmonary wedge capillary pressure, systemic vascular
resistance, and successful withdrawal of dobutamine.
With a power of 80% and an estimated 45% reduction in
BNP level between losartan and placebo, the calculated
sample size was 18 patients. As a secondary endpoint, we
estimated rates of successful withdrawal of 17% and 68% for
patients in the placebo group and the ARB group,
respectively, on the basis of our previous study (11).
Intervention procedures
Patients were allocated to the losartan or placebo group.
Losartan or placebo was administered at 25 mg bid and
increased to 50 mg bid 3 days later. The procedures were
performed in a double-blind fashion for the first 7 days to
control hemodynamic effects and for at least 3 more days
until the attempt at dobutamine withdrawal. Captopril was
the standardized ACE inhibitor used and was maintained
unchanged during the double-blind period.
Hemodynamic monitoring
The patients underwent pulmonary artery catheterization,
and cardiac output was obtained using the thermodilution
technique (12). The hemodynamic data obtained included
cardiac index, pulmonary artery pressure, pulmonary capil-
lary wedge pressure, and right atrium pressure. Indexed
systemic vascular resistance and indexed pulmonary vascu-
lar resistance were calculated. Hemodynamic measurements
were performed at baseline and 7 days after the start of the
intervention. The patients retained a percutaneous sheath
introducer, and pulmonary artery catheters were used only
for these two measurements.
BNP levels were measured using the automated immu-
noassaymethod at baseline and 7 days later. BNP serum levels
were transformed by logarithmic correction. Subsequently,
the changes incurred in the losartan and placebo groups were
assessed by repeated-measures ANOVA.
Adverse events
Adverse events included the occurrence of hypotension
(systolic blood pressure below 70 mm Hg), hyperkalemia (K
above 6.0 mEq/L), and worsening renal function (serum
creatinine above 3.0 mg/dL). If the systolic blood pressure
dropped below 70 mmHg, the daily dose of losartan or
placebo was reduced by half. If this hypotension persisted,
losartan or placebo was suspended.
Statistical analysis
The analysis was performed on an intention-to-treat basis
and included all randomized patients. Continuous variables
are expressed as the mean and standard deviation and were
compared between the ARB and control groups by
Student’s t test. Categorical variables are expressed as
numbers and proportions and were compared using the chi-
square test or Fisher’s test. Continuous variables at baseline
and after the intervention were analyzed between groups
using repeated measures ANOVA (13). P-values,0.05 (2-
tailed) were considered significant.
Clinical interest variables or variables with p,0.100 by
bivariate analysis underwent multivariate analysis by
logistic regression (14) to calculate the odds ratios and
respective 95% confidence intervals. Event free survival
curves were constructed using the Kaplan-Meier method
(15) and compared using the log-rank test (16). The
mortality predictors were identified by Cox regression (17).
This study was approved by the research ethics
committee of our institution and is registered with the
Brazilian Health Ministry and with the Clinical Trials
(www.clinicaltrials.gov; NCT 01857999). The patients or
their guardians read and signed the informed consent form.
This study was conducted according the principles of the
Helsinki Declaration (2004).
& RESULTS
We selected 21 patients between August 2008 and
December 2010. The characteristics of the included patients
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were as follows: age 52.7 (SD= 11.5) years, ejection fraction
21.3% (SD=5.8), dobutamine infusion 8.5 (SD= 3.8) mcg/
kg.min, systolic blood pressure 98.5 (SD=12.2) mmHg,
pulmonary wedge capillary pressure 30.7 (SD=7.7) mmHg,
indexed systemic vascular resistance 1,918 (SD= 556)
dynes.sec.cm-5.m-2, systemic vascular resistance 1,132
(SD= 371) dynes.sec.cm-5, cardiac index 2.8 (SD= 0.7) L/
min.m2, and BNP 1,403 (SD= 950) pg/mL. There were 10
(47.6%) patients with Chagas disease. See Table 1 for the
complete baseline characteristics.
After 7 days, the BNP levels decreased (Figure 1) by 37.4%
in the losartan group and increased by 11.9% in the placebo
group (mean difference -49.1%; 95% CI: -88.1 to -9.8%,
p= 0.018).
There was no significant difference in the hemodynamic
measurements. The systolic blood pressure decreased by
5.9% in the losartan group and by 3.2% in the placebo group
(p=0.796). The indexed systemic vascular resistance
decreased by 7.7% in the losartan group vs. 10.5% in the
placebo group (p= 0.280). The cardiac index increased by
6.7% and 6.9% in losartan and placebo groups, respectively
(p=0.203). The pulmonary capillary wedge pressure
decreased by 22.9% and 5.1% in the losartan and placebo
groups, respectively (p= 0.459). There were no complica-
tions related to the pulmonary artery catheter.
Successful dobutamine withdrawal occurred in 4/10
(40%) patients in the losartan group vs. 3/11 (27.3%)
patients in the placebo group (p= 0.537 by logistic regres-
sion). The odds ratio was 1.78 (95% CI: 0.20 to 16.4) for
successful dobutamine withdrawal in the losartan group.
The occurrence of adverse events was similar in both
groups. A drop in systolic blood pressure below 70 mm Hg
occurred in 3 (30%) patients in the losartan group and in 1
(9.1%) patient in the placebo group (p= 0.223); however, no
persistent hypotension occurred. None of the patients in
either group had hyperkalemia. Two patients (one patient
from each group) had an increase in serum creatinine
(.0.3 mg/dL) (p= 0.943). See Table 2 for changes in the
laboratory measurements.
After a follow-up of 465 days (95% CI: 317 to 613), 10
patients died (5 in each group) (p= 0.640), as shown in
Figure 2. Cox regression identified heart failure with
ischemic etiology as an independent predictor of all-cause
mortality, with a relative risk of 14.3 (95% confidence
interval: 1.6 to 130.0, p= 0.019).
& DISCUSSION
The main finding of this study was the decline in BNP
levels with angiotensin-receptor blocker add-on therapy in
patients with acute decompensated heart failure and a low
cardiac output state. Systemic vascular resistance, cardiac
index, and pulmonary wedge capillary pressure remained
unchanged, as did the clinical endpoint. These findings are
based on 42 hemodynamic and BNP measurements in 21
patients.
The novelty of the present study lies in the demonstration
of a more intense reduction in BNP levels (37.4%) with add-
on ARB therapy during decompensation (compared with
25% in stable outpatients). Moreover, this effect was
achieved in a 7-day period, whereas a 22-week period was
reported in a previous study (18). In another study with
stable class II-III heart failure patients, candesartan add-on
Table 1 - Baseline characteristics.
Characteristic Losartan (N=10) Placebo (N=11)
Age (SD); years 48.1 (12.7) 55.7 (9.8)
Men (%) 8 (80) 8 (72.7)
Ejection fraction (SD); % 20.4 (4.2) 22.1 (6.9)
Dobutamine dose (SD); mcg.kg-1.min-1 7.2 (2.8) 9.6 (4.3)
Cardiac index (SD); L.min-1.m-2 2.98 (0.36) 2.64 (0.86)
Indexed systemic vascular resistance (SD); dynes.sec.cm-5.m-2 1,755 (294) 2,052 (689)
Systemic vascular resistance (SD); dynes.sec.cm-5 1,022 (244) 1,234 (445)
Pulmonary wedge capillary pressure (SD); mmHg 30.0 (4.6) 31.2 (9.8)
Captopril dose (SD); mg/d 138.8 (35.6) 129.6 (35.0)
Carvedilol (%) 6 (60.0) 9 (81.9)
Furosemide (%) 9 (90) 10 (91)
Sodium (SD); mEq/L 133.2 (3.7) 134.3 (4.3)
Potassium (SD); mEq/L 4.23 (0.41) 4.12 (0.43)
Urea (SD); mg/dL 63.8 (35.8) 59.4 (18.3)
Creatinine (SD); mg/dL 1.21 (0.44) 1.25 (0.30)
BNP; median (interquartile range); pg/mL 1,259.5 (718.5 to 2,035.0) 1,046.5 (604.5 to 2,061.0)
Hemoglobin (SD); g/dL 13.4 (1.2) 11.4 (1.0)
SD: standard deviation; BNP: B-type natriuretic peptide.
Figure 1 - BNP evolution according to losartan or placebo group.
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therapy reduced amino-terminal proBNP by 20% in 6
months (19). Different from stable heart failure patients,
the management of patients with decompensation requires
specific strategies. For this reason, add-on ARB therapy
could be more important during heart failure decompensa-
tion, when BNP levels and neuro-hormonal activation are
higher (4).
A generally low cardiac output state during decompensa-
tion of heart failure is often neglected in randomized clinical
trials. Moreover, patients with unsuccessful withdrawal of
inotropic therapy have mortality rates higher than 79% (20).
Our findings could be particularly important for inotrope-
dependent heart failure patients who are not able to receive
a heart transplant. For these patients, the effects of drug
therapy should be faster and more intensive than for
patients with mild disease.
In addition, the lower ejection fraction, the low cardiac
output, the higher systemic vascular resistance, and the
higher BNP levels demonstrated the severity of heart failure
in our patients.
Hemodynamic condition during heart failure
decompensation
We found high systemic vascular resistance and high
pulmonary capillary wedge pressure in our patients during
acute heart failure decompensation. The high systemic
vascular resistance occurred despite the fact that the patients
were taking a high dose of an ACE inhibitor (captopril:
134 mg/d). In fact, Parker et al. observed a reduction in
systemic vascular resistance in patients with severe heart
failure who were taking ACE inhibitors; however, this
resistance remained above the normal values (21,22). The
cardiac index was normal; however, all patients were using
intravenous inotrope. Our findings are similar to those of the
Escape trial, which justifies the use of multiple vasodilators
with add-on ARB therapy. Interestingly, hemodynamic
improvement in the placebo group occurred even though
all medications remained unchanged. Non-pharmacological
factors could be involved in this finding, such as rest, salt
restriction, physiotherapy, and the ‘‘inertial’’ effect of drug
therapy before the hemodynamic measurements.
Table 2 - Changes in variables.
Variable Losartan (N=10) Placebo (N=11) p-value
Potassium (SD); mEq/L; at baseline 4.2 (0.4) 4.1 (0.4)
Potassium (SD); mEq/L; on 7th day 4.3 (0.5) 4.3 (0.4) 0.959
Creatinine (SD); mg/dL; at baseline 1.21 (0.44) 1.25 (0.30)
Creatinine (SD); mg/dL; on 7th day 1.15 (0.33) 1.15 (0.29) 0.911
BNP; median (IQR); pg/mL; at baseline 1,259.5 (1,318) 1,046.5 (1,457)
BNP; median (IQR); pg/mL; on 7th day 895.5 (814) 1,003.0 (1001.0) 0.016
SD: standard deviation; BNP: B-type natriuretic peptide; IQR: interquartile range;
P-value from inter-group comparison.
Figure 2 - Survival curves according to losartan or placebo.
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Dobutamine is indicated for low cardiac output in severe
heart failure based on International Guidelines; however, a
meta-analysis describing concerns regarding the increase in
mortality has been published (23). Nevertheless, this meta-
analysis included outpatients who received intermittent
therapy. Despite these concerns, in practice, physicians
continue to prescribe dobutamine to 22.3% of patients who
are hospitalized for heart failure (24,25). Consequently, our
results showed that add-on ARB therapy is an alternative to
this high-risk situation (i.e., low cardiac state and inotrope
dependence).
ARB-ACE inhibitor association pathophysiology
The renin-angiotensin-aldosterone system plays an
important role in the pathophysiology of heart failure. In
systolic heart failure, activation of this system occurs, which
worsens cardiac remodeling and hemodynamic conditions,
creating a vicious cycle. The blockade of this system with
an ACE inhibitor and an aldosterone antagonist reduces
morbidity and mortality.In addition, the renin-angiotensin-
aldosterone system interacts with the cardiac peptide
system. Plasma BNP levels increase in heart failure due to
BNP release by myocytes after distension. BNP has
diagnostic and prognostic values in heart failure (26).
Used as a guide for heart failure treatment, BNP reduces
death, hospital admission, and decompensation, most likely
through higher doses of diuretics, ACE inhibitors, and
spironolactone (27,28,29). However, the use of biomarkers
such as BNP as a surrogate endpoint remains controversial.
The ARB-ACE inhibitor association has been proven to be
beneficial in reducing clinical events such as cardiovascular
mortality and hospitalization (8,9). In our study, we applied
the tactic of ARB add-on therapy in patients with more
severe heart failure during decompensation and low cardiac
output, and we found a hormonal benefit. The survival
analysis did not identify a difference between the losartan
and placebo groups; however, the procedures were per-
formed in a double-blind fashion for 7 days, and it is very
unlikely that a short-term intervention could have an
influence on late outcomes.
The HEAAL study demonstrated that a high dose of
losartan reduces the endpoint rate compared with a low
dose (30). The occurrence of hyperkalemia was 2.79% in
the high-dose group and 1.87% in the low-dose group
(p,0.001); creatinine was also increased in the high-dose
group (7.12%) compared with the low-dose group (4.73%)
(p,0.001).
This association has been demonstrated to be beneficial
for patients on hemodialysis, leading to a significant
reduction in mortality and hospitalization (31). Adverse
effects—mainly hypotension—occurred in 16.3% of patients
in the ARB group versus 10.7% of patients in the placebo
group.
Safety of the ARB-ACE inhibitor association
Safety is another concern related to the ARB-ACE inhibitor
association. In the present study, the ARB-ACE inhibitor
association did not increase the occurrence of adverse effects
in the short-term. Use of this association for treatment of
hypertension did not reduce cardiovascular events; rather, it
increased adverse effects (32). On the other hand, in heart
failure patients, this association decreased mortality and
hospitalization with an increase of approximately 5% in
adverse effects (8,9). In addition, a meta-analysis (33)
revealed a 2.3% increase in the risk of developing an adverse
event. However, patients with more advanced heart failure
are the minority in these studies. The occurrence of adverse
events could be more frequent in patients with more severe
disease, although the benefit could be greater. Moreover,
worsening renal function has special importance because it
has been related to a worse prognosis in severe heart failure
(34).
Study limitations
The sample size of our study was small; thus, the analysis
of clinical events was somewhat challenging. Our primary
endpoint was a change in BNP, which is a surrogate
endpoint for clinical events. It is possible that the high
percentage of Chagas disease cardiomyopathy interfered
with our results because these patients have attenuated
vasoconstriction; consequently, multiple vasodilation stra-
tegies were not as effective as we expected.
In summary, short-term add-on therapy with losartan
reduced BNP levels in patients hospitalized for decom-
pensated severe heart failure and low cardiac output with
inotrope dependence. A non-significant hemodynamic
improvement and an increase in the probability of success-
ful dobutamine withdrawal were observed.
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